Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Envista HoldingsMEX:NVST 80 Piotroski F-Score is 8 as of Jul. 22, 2026, which is 60% above its 10-year median of 5.00. GuruFocus rates MEX:NVST with a GF Score™ of 80/100 and a GF Value™ of MXN332.83. The stock has 4 warning signs investors should review. Among 803 Medical Devices & Instruments companies, Envista Holdings ranks better than 98.75% on this metric.
Good Sign:
Piotroski F-Score is 8, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Envista Holdings has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Envista Holdings's Piotroski F-Score or its related term are showing as below:
MEX:NVST'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 5 Max: 9
Current: 8
During the past 10 years, the highest Piotroski F-Score of Envista Holdings was 9. The lowest was 2. And the median was 5.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Envista Holdings Piotroski F-Score Related Terms
Envista Holdings Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Envista Holdings's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NVST vs MMSI, MMED, STVN: Piotroski F-Score Comparison
For the Medical Instruments & Supplies subindustry, Envista Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Envista Holdings Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Envista Holdings's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Envista Holdings's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Mar26) TTM:
Last Year (Mar25) TTM:
Net Income was 497.091 + -555.829 + 592.388 + 697.865 = MXN1,232 Mil. Cash Flow from Operations was 1670.15 + 1443.689 + 1944.616 + -59.508 = MXN4,999 Mil. Revenue was 12843.397 + 12288.78 + 13515.078 + 12722.07 = MXN51,369 Mil. Gross Profit was 6964.921 + 6791.023 + 7393.14 + 7034.556 = MXN28,184 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(111832.705 + 106656.121 + 103507.149 + 102254.37 + 100586.401) / 5 = MXN104967.3492 Mil. Total Assets at the begining of this year (Mar25) was MXN111,833 Mil. Long-Term Debt & Capital Lease Obligation was MXN27,960 Mil. Total Current Assets was MXN34,607 Mil. Total Current Liabilities was MXN14,185 Mil.
Net Income was -21097.431 + 161.46 + 25.027 + 368.248 = MXN-20,543 Mil.
Revenue was 11598.457 + 11833.87 + 13616.687 + 12620.664 = MXN49,670 Mil. Gross Profit was 5983.346 + 6247.732 + 7768.748 + 6873.955 = MXN26,874 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(108810.027 + 99626.552 + 108507.336 + 111588.423 + 111832.705) / 5 = MXN108073.0086 Mil. Total Assets at the begining of last year (Mar24) was MXN108,810 Mil. Long-Term Debt & Capital Lease Obligation was MXN28,836 Mil. Total Current Assets was MXN37,842 Mil. Total Current Liabilities was MXN17,866 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Envista Holdings's current Net Income (TTM) was 1,232.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Envista Holdings's return on assets of this year was 0.01101212. Envista Holdings's return on assets of last year was -0.18879414.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Envista Holdings's gearing of this year was 0.2663657. Envista Holdings's gearing of last year was 0.26681808.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Envista Holdings's current ratio of this year was 2.43974066. Envista Holdings's current ratio of last year was 2.11805797.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Envista Holdings's number of shares in issue this year was 166.4. Envista Holdings's number of shares in issue last year was 173.6.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Envista Holdings's gross margin of this year was 0.54864727. Envista Holdings's gross margin of last year was 0.54105003.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Envista Holdings's asset turnover of this year was 0.45934081. Envista Holdings's asset turnover of last year was 0.45648071.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
1
+
1
+
1
+
1
+
1
+
1
=
9
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Envista Holdings has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.
Envista Holdings (MEX:NVST) has a Piotroski F-Score of 8 as of Jul. 22, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Envista Holdings and its competitors. This is 60% above median its historical median of 5.00. Over the past decade, Envista Holdings' Piotroski F-Score has ranged from 2.00 to 9.00. According to the industry distribution chart, Envista Holdings ranks #10 out of 803 companies in the Medical Devices & Instruments industry, placing it in the top 1.2%.
Is Envista Holdings' Piotroski F-Score too high?
Envista Holdings' current Piotroski F-Score of 8 is 60% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 9.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Envista Holdings' value of 8 is 60% above this industry median. Based on the distribution chart, Envista Holdings ranks #10 out of 803 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Envista Holdings has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Envista Holdings' Piotroski F-Score compare to MMSI and MMED?
According to the Medical Devices & Instruments industry distribution chart, Envista Holdings ranks #10 out of 803 companies for Piotroski F-Score. This places Envista Holdings in the top 1% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Envista Holdings' value of 8 is 60% above this benchmark. Historically, Envista Holdings' own Piotroski F-Score has ranged from 2.00 to 9.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Envista Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Envista Holdings's current Piotroski F-Score of 8 is 60% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Envista Holdings and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Envista Holdings's current Piotroski F-Score is 8, which is 60% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Envista Holdings stock overvalued right now?
Envista Holdings (MEX:NVST) has a current Piotroski F-Score of 8. The stock's GF Value™ is MXN332.83, compared to a current price of MXN370.00 — trading 11.2% above its estimated fair value. The current Piotroski F-Score is 8, which is 60% above median its 10-year median of 5.00 and 60% above the Medical Devices & Instruments industry median of 5.00. Envista Holdings' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Envista Holdings (MEX:NVST), the current Piotroski F-Score is 8 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Envista Holdings (MEX:NVST) Overvalued in 2026?
Based on GuruFocus' analysis, Envista Holdings stock appears to be overvalued.
The current stock price of MXN370.00 is trading 11.2% above its estimated GF Value™ of MXN332.83.
Key valuation signals for MEX:NVST:
Piotroski F-Score: 8 (60% above median its 10-year median of 5.00)
GF Value™: MXN332.83 vs. price of MXN370.00 (11.2% above fair value)
Industry Position: 60% above the Medical Devices & Instruments median (#10 of 803)
No single metric tells the full story. See the MEX:NVST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
80GF Score
Get the complete analysis for MEX:NVST
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NVST has been successfully added to your 
